23andMe Investor Presentation Deck
January 2024, 39 slides
  1. 23andMe
  2. Related Decks
  3. Investor Presentation Decks
therapeutics | 23andMe
| 23andMe
therapeutics genetics our value proposition | 23andMe
using human genetics to create meaningful therapeutics for diseases with high unmet need in oncology and immunology | 23andMe
the power of our approach | 23andMe
leaders in data target discovery | 23andMe
| 23andMe
| 23andMe
the initial foundation for genome analysis scree am ate | 23andMe
breadth of elucidates critical disease drivers | 23andMe
power immune genetics implemented as an clinical | 23andMe
power combining extensive in the and computational biology for target discovery | 23andMe
utilizing the world human map to address unmet medical need | 23andMe
need our unique approach to risk development be a | 23andMe
need our efforts leverage to identify targets in defined areas of medical need in asthma | 23andMe
progression of therapeutics at speed | 23andMe
speed our in house in antibody and protein engineering enables rapid therapeutic generation | 23andMe
speed our lead program progressed from discovery to the clinic in years i | 23andMe
therapeutics clinical development | 23andMe
experienced clinical development leadership | 23andMe
therapeutics pipeline first in class potential | 23andMe
me anti antibody for hard to treat solid tumors phase a me | 23andMe
development rationale so | 23andMe
me a fully humanized inhibits | 23andMe
phase results dose duration of treatment | 23andMe
preliminary clinical activity in cancer | 23andMe
phase a data estimated coe tay | 23andMe
| 23andMe
| 23andMe
next steps | 23andMe
me genetically validated cell activator anti antibody for metastatic solid tumors me | 23andMe
| 23andMe
| 23andMe
therapeutics target discovery | 23andMe
experienced discovery leadership | 23andMe
leveraging to expand airway target space | 23andMe
strategic sequencing based on polygenic risk scores | 23andMe
in respiratory disease beyond | 23andMe
therapeutics | 23andMe
See More
23andMe
Investor Presentation Decks
Diagnostics & Research Decks
Healthcare Decks
Explore Topics
Tumor
Clinical development
Solid tumor
Clinical trial
Recent decks by 23andMe
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
See all presentations by 23andMe (7 decks)
Related decks
Erasca
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
January 2024
Mink Therapeutics
IPO
October 2021
Alkermes
Investor Day
March 2021
BioNTech
Results
August 2021
Immix Biopharma
Investor Presentation
November 2023
Recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
Erasca
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
January 2024
Mink Therapeutics
IPO
October 2021
Alkermes
Investor Day
March 2021
BioNTech
Results
August 2021
Immix Biopharma
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io